Supernus Pharmaceuticals Inc (SUPN)

Payables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cost of revenue	US$ in thousands	0	467,442	382,420	257,436	176,585
Payables	US$ in thousands	—	10,543	9,331	6,147	10,141
Payables turnover		—	44.34	40.98	41.88	17.41

December 31, 2023 calculation

Payables turnover = Cost of revenue ÷ Payables
= $0K ÷ $—K
= —

Supernus Pharmaceuticals Inc's payables turnover has shown a significant improvement over the past five years. The payables turnover ratio increased from 1.64 in 2019 to 42.66 in 2023, indicating that the company is managing its accounts payable more effectively. This means that Supernus Pharmaceuticals is paying its suppliers more frequently relative to the amount outstanding, which can be a positive sign of efficient cash management and strong vendor relationships. The substantial increase in the payables turnover ratio suggests that the company has been able to negotiate more favorable payment terms with its suppliers or has enhanced its operational efficiency in managing payables. Overall, the upward trend in payables turnover is a positive indication of Supernus Pharmaceuticals' financial health and effective working capital management.